Aster Insights Announces Presentations at SITC’s 38th Annual Meeting

Aster Insights has announced that it will participate in the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting this November, with three presentations on the agenda. This year’s SITC Annual Meeting will be held in San Diego, CA, from November 1-5. Presenters from Aster Insights include Tim Shaw, Xuefeng Wang, and Michael Radmacher.

The abstracts on which the presentations are based were published this week in the Journal for Immunotherapy of Cancer (JITC). A full event agenda, as well as the presented abstracts can be viewed on the SITC website.

“These presentations at SITC are a testament to the longstanding partnerships between Aster Insights and ORIEN,” said Anand Shah, MD, Aster Insights CEO. “Over the years, our collaborative research in immuno-oncology has identified new treatments, supported drug and biomarker discovery, and provided novel insights for cancer care delivery.”

Presentation details:

Genetic heterogeneity between paired primary and metastatic solid tumors and implications for neoantigen-based personalized cancer vaccines

Global and local copy number aberration signatures as prognostic and immunotherapeutic predictors

Demonstration of the utility of real-world progression-free survival (rwPFS) by application of an IFN-γ-related signature in a real-world cohort of patients with melanoma

For more details about the abstract presentations, including abstract numbers and descriptions, please visit the Aster Insights website.

Read the abstracts in the Journal for Immunotherapy of Cancer (JITC).